Ayahuasca?s therapeutic potential: What we know-and what not

被引：18

作者：

Maia, Lucas Oliveira ^{[1
,2
,3
]}

Daldegan-Bueno, Dimitri ^{[1
,4
]}

Wiessner, Isabel ^{[1
,2
]}

Araujo, Draulio B. ^{[2
,5
]}

Tofoli, Luis Fernando ^{[1
]}

机构：

[1] Univ Campinas UNICAMP, Sch Med Sci, Interdisciplinary Cooperat Ayahuasca Res & Outrea, Campinas, Brazil

[2] Fed Univ Rio Grande do Norte UFRN, Brain Inst, Natal, RN, Brazil

[3] Fed Univ Alfenas UNIFAL MG, Interdisciplinary Ctr Studies Palliat Care CIECP, Sch Nursing, Alfenas, Brazil

[4] Simon Fraser Univ, Fac Hlth Sci, Ctr Appl Res Mental Hlth & Addict CARMHA, Vancouver, BC, Canada

[5] Fed Univ Rio Grande do Norte UFRN, Hosp Univ Onofre Lopes, Natal, RN, Brazil

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2023年 / 66卷

关键词：

Ayahuasca; Psychedelics; 5-HT2A receptor; Psychiatric disorders; Neurodegenerative diseases; Serious illness; PSYCHOACTIVE BEVERAGE AYAHUASCA; DEFAULT MODE NETWORK; SIGMA-1; RECEPTOR; RECURRENT DEPRESSION; BANISTERIOPSIS-CAAPI; PSYCHIATRIC-SYMPTOMS; ALKALOID EXTRACT; DRUG-DEPENDENCE; HEALTH-STATUS; USERS;

D O I：

10.1016/j.euroneuro.2022.10.008

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

However, a growing body of evidence suggests that other conditions equally relevant to public health might be promising targets for ayahuasca's therapeutic effects. This includes preliminary studies indicating potential for grief, eating disorders, posttraumatic stress disorder, personal-ity disorders, Parkinson's and Alzheimer's disease, and severe physical illnesses (e.g., cancer, chronic conditions). Moreover, preliminary evidence in long-term ayahuasca users does not sug-gest detrimental effects but possible benefits for individual and collective health. In light of the emerging evidence of psychedelic drugs as therapeutic agents, it is essential to further investigate in rigorous designs the therapeutic potential of ayahuasca in conditions other than depression.(c) 2022 Elsevier B.V. and ECNP. All rights reserved.

引用

页码：45 / 61

页数：17

共 173 条

[1]

Aday J.S., 2020, DRUG SCI POLICY LAW, V6, DOI [10.1177/2050324520974484, DOI 10.1177/2050324520974484]

[2] Pre-clinical investigations of β-carboline alkaloids as antidepressant agents: A systematic review [J].